Horizon Acquires Sage Labs Inc. for $48M (£29M)
News Oct 01, 2014
Horizon Discovery Group plc has announced that it has agreed to acquire Sage Labs Inc. (Sage) for up to $16M (£9.8M) in cash and up to $32M (£19.6M) through the issue of new ordinary shares. The acquisition of Sage, a world leader in the generation of advanced in vivo transgenic disease models for use in preclinical research, builds upon the acquisition of CombinatoRx in July and makes Horizon the world’s leading gene-editing company and the go-to company for the provision of integrated product, service and research solutions at all stages of translational genomics and personalized medicine research from sequence to treatment.
The acquisition, which is in line with the stated strategy to build a fully-integrated life science business, provides Horizon with an expanded range of genetically engineered preclinical models, important tools for the discovery and development of medicines targeted to the unique genetic drivers of diseases like cancer.
The combined gene-editing platform diversifies Horizon’s overall product and service offerings into adjacent markets not currently addressed, increases its cost consolidation and cross selling potential as well as strengthens its intellectual property portfolio. Sage also provides Horizon with long-term organic innovation opportunities and deep customer relationships within the industry which complement Horizon’s existing business lines.
Sage, a former business within Sigma-Aldrich, was known as Sigma Advanced Genetic Engineering and became Sage Labs Inc. when it was purchased by management and Telegraph Hill Partners in 2013. Sage has benefitted from in excess of $25 million of past investment.
The company has 50 employees, a direct US and EU sales force and 43,000 sq. ft. facilities, enabling the scale-up of Horizon’s product and service offerings through access to new capabilities, capacity and access to new markets.
Horizon will gain exclusive access to ZFN for in vivo model generation and certain exclusive and non-exclusive CRISPR in vivo-related intellectual property (IP) to add to its extensive in vitro IP in CRISPR, ZFN and rAAV, the latter of which is a world-wide exclusive to Horizon. Assets and capabilities acquired include a custom engineered in vivo model development service, an inventory of ready to use in vivo models and an inventory of molecularly annotated patient-derived xenograft (PDx) models and custom development capabilities.
Horizon will focus on expanding Sage’s predominantly US customer base by increasing its presence in Europe, Japan and beyond via access to Horizon’s business development and commercial infrastructure and an almost 1,000 strong customer base.
The acquired business will be known as Sage Labs Inc., a wholly owned subsidiary of Horizon Discovery Group plc. Horizon will also benefit from adding further strong leadership capability to its world-class management team. Successful serial entrepreneur Dr David Smoller, formerly CEO of Sage, and previously CSO of Sigma-Aldrich and President of its Research Biotechnology business unit, will become Horizon’s Chief Business Officer.
Along with Dr Darrin M Disley, CEO of Horizon, David will lead the implementation of the long-term corporate development strategy. Dr Edward Weinstein will become General Manager of Sage and will lead a team with decades of experience in preclinical model development and commercialization.
The acquisition is expected to complete on 2 October 2014.
Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “The acquisition positions Horizon as the world-leader in gene-editing and at the forefront of technological advances in the field of translational genomics. The consolidated offering significantly strengthens Horizon commercially, allowing us to offer product, service and R&D programs to customers engaged at every stage of translational genomics and personalized medicine research from sequence to treatment.”
Dr David Smoller, Chief Executive Officer of Sage Labs Inc., added: “I am excited that Sage has become a part of Horizon’s important mission. Horizon is now the destination for researchers and scientists worldwide to find both in vivo and in vitro solutions to their biological questions. The addition of Sage now positions Horizon as the true leader in genomics and gene-editing.”
Further details of the acquisition
• Application has been made to the London Stock Exchange for 10,957,877 consideration shares to be admitted to trading on AIM (“Admission”). It is expected that Admission will become effective and that trading in the new Ordinary Shares will commence on 2 October 2014.
• $15.2 million (£9.3 million) in cash is payable and 10,957,877 new ordinary shares representing $30.4 million (£18.6 million) of the consideration will be issued by Horizon on closing of the acquisition. $0.8 million (£0.5 million) in cash may be payable and new ordinary shares representing $1.6 million (£1.0 million) of the consideration may be issued by Horizon 12 months after the closing of the acquisition.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.